Abstract:Background: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology)of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.Whilst bromocriptine treatment for reducing prolactin levels in hyperprolactinaemic males (as in females), and, in the treatment of hypogonadotropic hypogonadism with hyperprolactinaemia, is beneficial, it has also been used for oligospermic men in the absence of any endocrinopathy. Prolactin may play a direct role in spermatogenesis and hormone production. It has also been claimed that in oligospermic men with normal gonadotrophins mean prolactin levels are higher and that hyperprolactinaemia is more common compared to fertile men. It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Although it is not licensed for use in male infertility, bromocriptine has been used for normogonadotrophic individuals with oligospermia and normal or slightly elevated prolactin levels. This review considers the available evidence of the effect of bromocriptine therapy for normoprolactinaemic males with idiopathic oligo and/or asthenospermia. Objectives: The objective of this review was to assess the effects of bromocriptine on pregnancy rates among couples where subfertility has been attributed to idiopathic oligo- and/or asthenospermia. Search strategy: The Cochrane Subfertility Review Group specialised register of controlled trials was searched". Selection criteria: Randomised trials of oral bromocriptine versus placebo or no treatment for couples with subfertility attributed to male factor. Data collection and analysis: Data were extracted by one reviewer and any disagreements were resolved by discussion with other reviewers. Main results: Four studies were included. The method of randomisation was not specified in any of the trials, which were all of crossover design. Compared with placebo, bromocriptine was associated with a significant reduction in serum prolactin levels (weighted mean difference -195.3 micro international units per litre, 95% confidence interval -276.5 to -114). No effects on sperm parameters were seen. There was also no effect on pregnancy rates observed between bromocriptine and placebo (0.70 odds ratio, 95% confidence interval 0.15 to 3.24). Authors' conclusions: Bromocriptine appears to reduce prolactin levels in subfertile men with normal gonadotrophic function. There is not enough evidence to show that bromocriptine is helpful in improving fertility.[This abstract was prepared centrally.].

Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: A systematic review and meta-analysis.

Gonadotropic responsiveness to clomiphene, LRH, estradiol, and bromocriptine in galactorrheic women

Meta-analysis of Effectiveness and Safety of Bromocriptine by Vaginal Delivery for Hyperprolactinemia in Chinese Female Patients

The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis

[Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function]

Treatment of hyperprolactinemia: a systematic review and meta-analysis

Curative Effect and Mechanism of Bromocriptine on Pituitary Prolactinoma

A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

WITHDRAWN: Bromocriptine for idiopathic oligo/asthenospermia

Bromocriptine for idiopathic oligo/asthenospermia

A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level

[Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia]

Surgery versus bromocriptine for female patients with prolactinoma in China:A Meta-a-nalysis

Bromocriptine. Clinical experience in the induction of pregnancy in amenorrhea-galactorrhea syndrome

AB086. the Effect of Xuanju Compound Capsule Combined with Bromocriptine

AB236. the Effect of Xuanju Compound Capsule Combined with Bromocriptine on Erectile Dysfunction Due to Hyperprolactinemia

Bromocriptine in hyperprolactinemic amenorrhea: a possible early effect on ovarian steroidogenesis

The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia

Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review

Efficacy of Moderate Dose Bromocriptine by One-off Oral Administration in Patients with Non-Acute Prolactin Type Pituitary Adenoma

Cabergoline Versus Bromocriptine for the Treatment of Giant Prolactinomas: A Quantitative and Systematic Review